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Stabilin-mediated cellular internalization of phosphorothioate-modified Antisense 
Oligonucleotides (ASOs)
Colton M. Miller*, Aaron J. Donner§, Emma K. Blank*, Andrew W. Egger*, Brianna M. Keller*, Punit P. 
Seth§, Edward N. Harris*
*University of Nebraska, Dept. of Biochemistry, Lincoln, NE  68588, §Ionis Pharmaceuticals, Inc., Carlsbad, CA 92010
The authors don’t have anything to disclose with the presented information.
Introduction: Antisense oligonucleotides (ASOs) are short chemically modified 
oligonucleotides (5-7.4 kDa) that can produce a pharmacological effect by binding to RNA 
and affecting intermediary metabolism. Over 35 phosphorothioate (PS) ASOs are at 
various stages of clinical development for use as therapeutic agents and pharmacological 
tools. Antisense therapy is a progressing area of research, as these small strands of 
nucleotide oligomers can be produced to silence genes that aggravate chronic disorders or 
infections. An important distinction for ASOs compared to DNA is the substitution of the 
phosphodiester (PO) backbone with the PS modification. This sulfur substitution allows for 
these polar polyanionic molecules to have high stability in biological fluids and selective 
binding to cell surfaces. Although there is a premium for clinical development of these short 
chain molecules, the current understanding of the pathways for their ability to traverse 
plasma membranes remains unresolved. Injected gymnotic ASOs have been shown to 
accumulate in the liver via the organ’s functional scavenging mechanism in highly 
endocytically active sinusoidal endothelial cells (SECs) and Kupffer cells (KC) compared to 
hepatocytes. Our work outlines how a non-DNA binding class of scavenger receptors 
known as Stabilins binds to, and internalizes these small PS ASOs. Methods: Primary 
cells from rat and mouse were isolated and cultured with 125I-ASOs. Stable cell lines 
expressing Stabilin-1 and two Stabilin-2 isoforms (315-HARE and 190-HARE), were used 
to analyze binding affinity, endocytosis and degradation of 125I-ASOs in the cell. Co-
localization was also done to analyze trafficking of ASOs once internalized within the cell 
by use of fluorescent ASO and lysotracker. Results: It was determined that PS ASOs bind 
with high affinity to the Stabilin class receptors with the majority of internalization performed 
by clathrin-mediated endocytosis. Binding was determined to be dependent on proper 
folding of the receptor, along with relying on salt-bridge formation. Once inside the cell via 
the Stabilin receptors, co-localization analysis showed ASOs being trafficked for 
degradation in the lysosome. Increased internalization rates of an ASO targeting the non-
coding RNA of malat-1, in the Stabilin-expressing cell lines reduced malat-1 expression 
more efficiently, indicating not all ASOs are trafficked to the lysosome after internalization. 
Conclusion: Our work shows that ASOs are internalized into the cells of the liver through 
clathrin-mediated endocytosis. The understanding of the pathway(s) for chemically 
modified ASO internalization and trafficking with cell surface receptors will aid in future 
clinical design of ASOs as therapeutic agents.
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Fig. 2:  Components of ASOs
Table. 1:  ASO polymers used in this study.  
Fig. 3: Half-life and tissue distribution in mice.  A)  
Intravascular injections in mice with 1.0 mg/kg 125I-ASO resulted 
in a half-life of 9 min in the blood.  B)  Approximately 20% of all 
ASO was contained in the liver.  C) Within the liver, over 80% of 
the ASO was in the non-parenchymal fraction and D) the highest 
distribution of ASO was in the LSECs.
Fig. 4: Stabilin receptor internalize ASOs.  A) Cell lysates on 
5% SDS-PAGE from HEK Flp-In 293 cells expressing parent pcDNA5 
(empty vector (EV)) (lane 1), Stabilin-1 (lane 2), Stabilin-2, 315-HARE 
(lane 3, black arrowhead), or Stabilin-2, 190-HARE (lane 4, open 
arrowhead) were probed with anti-V5 to visualize recombinant protein 
expression and anti-vinculin as load control (black arrow).  B) All four 
cell lines were subject to 0.1 mM 125I-ASO over 9 hrs. C) At least half of 
the internalization is regulated by clathrin-mediated endocytosis (gray 
bars) in contrast to untreated controls (black bars).  D) A small 
increase in binding occurs with the 190-HARE cells and not with the 
other cell lines when compared with EV indicating that Stabilin 
receptors are primarily involved with endocytosis of ASO from the cell 
surface.   NS = not significantly different from control. * is p=0.038.
Abstract Results
Fig. 5: Binding characteristics of ASO and 190-HARE. A) Purified 
190-HARE or BSA was plated in polysorp wells and incubated with 
increasing concentrations of 125I-ASO.  B) 0.05 mM 125I-ASO was incubated 
with increasing concentrations of NaCl to disrupt ionic bonding, urea to 
disrupt hydrogen bonding, or guanidinium chloride to disrupt protein folding.
Fig. 6: Endocytosis with competition.  
All four cell lines were incubated with 0.1 mM
125I-ASO in the presence of 20 mM
competitor as indicated for up to 90 min.
Fig. 7: Competition in both 190-HARE and rat primary LSECs. 
A) 190-HARE and B) rat LSECs were incubated with 0.1 mM 125I-ASO 
with 20 mM the indicated competitors for 90 min showing similar 
uptake values.  
Fig. 8: Stabilin receptors traffick ASO to lysosomes. A)  EV and 190-
HARE cells were incubated with 0.05 mM Cy3-ASO (red) for 1, 3, or 6 hrs and 
then incubated with 1.0 mM Lysotracker (green) for 25 min. and imaged by 
confocal microscopy.  Images were processed with Fiji Coloc-2 software and the 
colocalization data was quantified in B.
Fig. 10: Degradation of ASO in cells.  EV, 190-HARE and 315-
HARE cells were incubated with 0.1 mM 125I-ASO for 2 hrs (pulse), 
washed with PBS, and incubated in fresh medium for 6 additional hrs
(chase).  The chase medium was subject to DEAE column 
chromatography to capture the ASO.  Degraded and partially degraded 
ASO was eluted with 0.4 M NaCl and intact ASO was eluted with 2.0 M 
NaCl.  A) The ratio of degraded to intact ASO was highest in the Stab2 
expressing cell lines in contrast to the EV.  B) Left: 125I-ASO was 
assessed for intrisic degradation in the prepartion indicated that at least 
80% was intact (black bars).  Mice were injected with 1.0 mg/kg 125I-
ASO and urine was collected over a 2 hr period resulting in the majority 
of ASO in urine is degraded.
Fig. 11: Efficient gene expression knockdown in Stabilin-
expressing cells. All four cell lines were incubated with 0.001-100 
mM ASO against malat-1, a long non-coding RNA, for A) 24 or B) 48 
hrs and assessed for malat-1 expression levels by qPCR.
Conclusions
• Liver is a primary site for ASO 
sequestration from blood.
• Stabilin-1 and both Stabilin-2 receptors 
increased internalization of ASOs from the 
cell surface.
• ASOs bind Stabilins via ionic bonding
• ASOs composed of phophorothioate
linkages and methoxyethyl modifications 
have higher affinities for the Stabilins than 
the morpholinos or phosphodiester ASOs.
• Internalization by the Stabilin receptors 
increases lysosome delivery which is a 
dead-end for ASOs, but receptor 
internalization also enhances gene knock-
down.
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Fig. 1:  The Stabilin receptors.  Stab1 and Stab2 are expressed in endothelium of liver, 
lymph node, spleen and bone marrow.  Both receptors are comprised of the same domain 
organization, although Stab1 does not have a functional LINK domain and cannot be categorized 
as a hyalectin.  Both receptors bind to heparin, GDF-15, phosphatidylserine, advanced glycation
end-products (AGE), and modified LDL.  Individually, Stab1 binds to lactogen and SPARC and 
Stab2 binds with HA, CS, and collagen pro-peptides.  Neither receptor binds natural DNA or RNA 
with phosphodiester backbones.  Both receptors undergo proteolytic cleavage/maturation with 
Stab1 expressed as isomers of nearly the same size in a 1:1 ratio and Stab2 expressed as 315-
and 190-kDa receptors in a 5:1 to 2:1 ratio depending on the tissue.      = EGF domain,        = 
Fas-1 domain,        = transmembrane domain,        = Link domain
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Fig. 9: Endocytosis with Drug Inhibitors.
Endocytosis of 0.1 µM 125I-ASO in EV (A), Stabilin-1 (B), 315-HARE (C), 
and 190-HARE (D) cell lines at one time point (90 mins) as either 
untreated control (black bars) or with drug/conditions (grey bars) that 
inhibit clathrin-mediated endocytosis.Dimethyl sulfoxide solvent control, 
P- 30.0 µM PitStop2, Dy-300 µM-Dynasore, Su-0.4 M sucrose.
